ES2425448B8 - Uso de la obestatina para la regeneración muscular - Google Patents

Uso de la obestatina para la regeneración muscular Download PDF

Info

Publication number
ES2425448B8
ES2425448B8 ES201230367A ES201230367A ES2425448B8 ES 2425448 B8 ES2425448 B8 ES 2425448B8 ES 201230367 A ES201230367 A ES 201230367A ES 201230367 A ES201230367 A ES 201230367A ES 2425448 B8 ES2425448 B8 ES 2425448B8
Authority
ES
Spain
Prior art keywords
muscle regeneration
obestatine
regeneration
muscle
obestatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES201230367A
Other languages
English (en)
Other versions
ES2425448B2 (es
ES2425448A1 (es
Inventor
Jesús PÉREZ CAMIÑA
Felipe CASANUEVA FREIJO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidade de Santiago de Compostela
Servizo Galego de Saude SERGAS
Original Assignee
Universidade de Santiago de Compostela
Servizo Galego de Saude SERGAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidade de Santiago de Compostela, Servizo Galego de Saude SERGAS filed Critical Universidade de Santiago de Compostela
Priority to ES201230367A priority Critical patent/ES2425448B8/es
Priority to EP13761384.0A priority patent/EP2862577B1/en
Priority to PCT/ES2013/070149 priority patent/WO2013135928A1/es
Priority to US14/384,766 priority patent/US20150094264A1/en
Publication of ES2425448A1 publication Critical patent/ES2425448A1/es
Application granted granted Critical
Publication of ES2425448B2 publication Critical patent/ES2425448B2/es
Publication of ES2425448B8 publication Critical patent/ES2425448B8/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2214—Motilins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de la obestatina para la regeneración muscular.#La presente invención se refiere al uso de la obestatina, o a la secuencia nucleotídica que la codifica, como agente miogénico “in vitro”, y para la elaboración de un medicamento para la regeneración muscular preferiblemente para la regeneración músculo-esquelética, siendo así de utilidad en el tratamiento y/o prevención de enfermedades degenerativas o genéticas o de lesiones que cursan con daño muscular.
ES201230367A 2012-03-12 2012-03-12 Uso de la obestatina para la regeneración muscular Expired - Fee Related ES2425448B8 (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ES201230367A ES2425448B8 (es) 2012-03-12 2012-03-12 Uso de la obestatina para la regeneración muscular
EP13761384.0A EP2862577B1 (en) 2012-03-12 2013-03-08 Use of obestatin for muscle regeneration
PCT/ES2013/070149 WO2013135928A1 (es) 2012-03-12 2013-03-08 Uso de la obestatina para la regeneración muscular
US14/384,766 US20150094264A1 (en) 2012-03-12 2013-03-08 Use of obestatin for muscle regeneration

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201230367A ES2425448B8 (es) 2012-03-12 2012-03-12 Uso de la obestatina para la regeneración muscular

Publications (3)

Publication Number Publication Date
ES2425448A1 ES2425448A1 (es) 2013-10-15
ES2425448B2 ES2425448B2 (es) 2014-11-07
ES2425448B8 true ES2425448B8 (es) 2015-03-17

Family

ID=49160293

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201230367A Expired - Fee Related ES2425448B8 (es) 2012-03-12 2012-03-12 Uso de la obestatina para la regeneración muscular

Country Status (4)

Country Link
US (1) US20150094264A1 (es)
EP (1) EP2862577B1 (es)
ES (1) ES2425448B8 (es)
WO (1) WO2013135928A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020058533A1 (en) * 2018-09-21 2020-03-26 Universidade De Santiago De Compostela Obestatin for use in the treatment of peripheral nerve damages or injuries

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087933A2 (en) * 2000-05-11 2001-11-22 Zymogenetics, Inc. Zsig33-like peptides
US20060229250A1 (en) * 2005-03-09 2006-10-12 Jian Zhang Ghrelin associated peptide and its uses
US20100323950A1 (en) * 2007-09-11 2010-12-23 Dorian Bevec Use of beta-melanotropin as a therapeutic agent, eg for the treatment of aids or alzheimer
WO2009033714A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
EP2350118B1 (en) * 2008-09-19 2016-03-30 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof

Also Published As

Publication number Publication date
EP2862577A4 (en) 2015-11-11
EP2862577B1 (en) 2017-08-02
EP2862577A1 (en) 2015-04-22
ES2425448B2 (es) 2014-11-07
US20150094264A1 (en) 2015-04-02
WO2013135928A1 (es) 2013-09-19
ES2425448A1 (es) 2013-10-15

Similar Documents

Publication Publication Date Title
WO2014052935A3 (en) Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
MX365835B (es) Uso de akkermansia para tratar trastornos metabolicos.
MX2017005834A (es) Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
CL2015000331A1 (es) Compuestos derivados de piridazina 1,4-disustitutidos; composicion y combinacion farmaceutica que los comprende y uso en el tratamiento de la atrofia muscular espinal.
CL2014003388A1 (es) Compuestos derivados de triazolona, como inhibidores de mpges-1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, util para el tratamiento de inflamacion, asma, epoc, artritis, enfermedad de parkinson y enfermedades autoinmunes, entre otras enfermedades.
WO2013188847A8 (en) Compositions and methods for transmucosal absorption
BR112015000150A2 (pt) composições farmacêuticas dissuasoras de abuso de liberação controlada
WO2013151665A3 (en) Modified polynucleotides for the production of proteins associated with human disease
BR112015010663A2 (pt) formas de dosagem de ruxolitinib de liberação sustentada
CL2012002606A1 (es) Composicion farmaceutica que comprende (-)-carvona, (+)-carvona, trans-geraniol y al menos un componente elegido de aceites esenciales para uso en el tratamiento y prevencion de enfermedades virales.
MX2014008705A (es) Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos.
CY1116304T1 (el) Χρηση της βιοτινης για τη θεραπευτικη αγωγη της σκληρυνσης κατα πλακας
CL2012002175A1 (es) Composicion farmaceutica oral de liberacion prolongada que comprende un agente activo de fracciones de propargilamina y aminoindano; metodo de preparacion; uso en el tratamiento de enfermedades neurodegenerativas o lesiones en el sistema nervioso tales como parkinson o alzheimer, un accidente cerebrovascular o lesion traumatica cerebral.
BR112012022552A2 (pt) uso de fenoterol e de anélogos de fenoterol no tratamento de gliobastomas e astrocitomas
MX2014008706A (es) Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos.
BR112014007902A2 (pt) composições farmacêuticas compreendendo 40-o-(2-hidróxi)etil-rapamicina
BR112013029256A2 (pt) "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina".
CL2014003325A1 (es) Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer
BR112012028773A2 (pt) composições farmacêuticas compreendendo hidromorfona e naloxona
MX2015005732A (es) Compuestos tricíclicos y métodos para hacer y utilizar los mismos.
WO2013173827A3 (en) Methods and compositions for inhibiting diseases of the central nervous system
BR112014021497A2 (pt) sistema de entrega de fármaco baseado em jcv-vlp
NI201700066A (es) Antagonistas de a2a de dosis baja para tratamiento de tdah y la enfermedad de parkinson
CL2014001776A1 (es) Composicion farmaceutica topica que comprende: a) bexaroteno, b) al menos 1 corticosteroide y c) un portador o vehiculo; uso para el tratamiento o la prevencion de trastornos de la piel, como psoriasis.
PE20151424A1 (es) Compuesto farmaceutico para la prevencion y el tratamiento de un trastorno o una enfermedad cognitivos, neurodegenerativos o neuronales

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2425448

Country of ref document: ES

Kind code of ref document: B2

Effective date: 20141107

FD2A Announcement of lapse in spain

Effective date: 20210928